4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

Industry Overview - Innovation is expected to drive growth in the biotech industry, particularly in obesity and oncology drugs, with strong M&A activity anticipated in 2025 [1] - The overall fundamentals of the biotech sector remain robust, and investor interest is expected to return [1][16] ADMA Biologics - ADMA Biologics markets plasma-derived biologics for immune deficiencies and infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [2] - The company has shown exceptional performance in 2024, with shares increasing by 292% year to date [3] - Earnings per share estimates for 2025 have risen from 64 cents to 78 cents in the last 60 days [4] - ADMA is working to increase Asceniv's supply, which is expected to significantly contribute to total revenues and margin expansion [20] Tarsus Pharmaceuticals - Tarsus Pharmaceuticals markets Xdemvy, an eye drop for Demodex blepharitis, which generated $113.7 million in sales in the first nine months of 2024 [5][22] - The company has experienced a share price increase of 168.7$2.10 to $1.43 in the past 60 days [7] Stoke Therapeutics - Stoke Therapeutics is developing zorevunersen for Dravet syndrome, currently in phase I/IIa studies, with Breakthrough Therapy designation granted by the FDA [8][9] - The company has seen a share price increase of 120.7$2.59 to $2.49 in the past 60 days [11] ChromaDex - ChromaDex markets Niagen as a leading NAD+ booster and is developing nicotinamide riboside chloride (NRC) for ataxia telangiectasia, with FDA designations granted [12][14] - The company has experienced a share price increase of 270.6% in 2024, driven by strong sales and e-commerce growth [15][28] - Earnings per share estimates for 2025 have increased from 9 cents to 12 cents in the past 60 days [15]